drugset
drugset / Trial / NCT02690337

Study of DS-1123a in Advanced Solid Tumours

NCT02690337 ↗

Phase 1 Completed 27 enrolled Daiichi Sankyo
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label study to evaluate the safety, tolerability, and pharmacokinetics of DS-1123a in Japanese subjects with advanced solid tumors.

Timeline

Start
2016-01
Primary completion
2017-11
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Subject DS-1123 Unknown 0.1 mg/kg Intravenous

Indications

cancer